iSpecimen (ISPC) Common Equity (2020 - 2026)

iSpecimen's Common Equity history runs 7 years deep, the most recent figure standing at $814038.0 for Q1 2026.

• In Q1 2026, Common Equity fell 51.21% year-over-year to $814038.0; the TTM figure through Mar 2026 stood at $814038.0 (down 51.21% YoY), while the FY2025 annual figure was $3.1 million, down 6.73% from the prior year.
• Common Equity for Q1 2026 stood at $814038.0, down from $3.1 million in the prior quarter.
• The five-year high for Common Equity was $27.7 million in Q1 2022, with the low at $621973.0 in Q2 2025.
• The 5-year median for Common Equity is $6.8 million (2024), against an average of $10.7 million.
• The sharpest annual moves came in 2022 and 2025: Common Equity surged 188.62% in 2022, then slumped 89.79% in 2025.
• iSpecimen's Common Equity stood at $20.3 million in 2022, then sank by 52.04% to $9.7 million in 2023, then sank by 66.01% to $3.3 million in 2024, then decreased by 6.73% to $3.1 million in 2025, then slumped by 73.64% to $814038.0 in 2026.
• Business Quant data shows ISPC's Common Equity at $814038.0 in Q1 2026, $3.1 million in Q4 2025, and $3.1 million in Q3 2025.